Loading organizations...
Key people at Dimension Ventures.
Dimension Ventures was founded in 2018 by John Smothers (Co-founder / Investor).
Dimension Ventures is a venture capital firm based in New York and San Francisco that invests in early-stage biotechnology and life sciences companies operating at the intersection of computing and drug discovery. The firm deploys initial check sizes ranging from $500,000 to $3 million into startups developing machine learning platforms, clinical trial software, and digital tools. After launching its inaugural $350 million fund to back approximately 20 to 25 startups, the firm began raising an estimated $700 million for a third fund. The firm's investment portfolio includes notable life sciences companies such as Enveda Biosciences, Lamin AI, and Kaleidoscope Bio, highlighted by leading a $68 million Series B funding round for Enveda. Dimension Ventures was founded in 2022 by former Lux Capital general partners Adam Goulburn and Zavain Dar, alongside former Obvious Ventures managing director Nan Li.
Key people at Dimension Ventures.
Dimension Ventures was founded in 2018 by John Smothers (Co-founder / Investor).
Dimension Ventures is a New York-based venture capital firm founded in 2023, focused on the intersection of technology and life sciences to "transform the trajectory of life on earth" by catalyzing advancements in compute and biology.[1][2][5] Its mission centers on partnering with founders building biotech platforms, software infrastructure, lab tools, clinical development, manufacturing, AI, and machine learning solutions for drug discovery and life sciences digitization.[1][4][5] With a $350 million debut fund fully deployed across 17 companies and a freshly raised $500 million second fund (Dimension II), the firm invests from incubation to growth stages, writing checks from $500K to $40 million, and has backed 22 portfolio companies with notable names like Modal Labs, Enveda, NewLimit, and Chai Discovery.[1][2][3][5] Dimension's philosophy emphasizes early-stage innovation in AI-driven biotech, where data scarcity creates high barriers and untapped potential, positioning it as a key player accelerating the startup ecosystem at the tech-bio frontier.[3][4]
Dimension was launched in January 2023 by three partners with deep roots in venture and science: Zavain Dar and Nan Li, computer scientists, and Adam Goulburn, a former stem cell researcher, who bonded while climbing the ranks at Lux Capital and Obvious Ventures.[2] Frustrated with larger firms, they spun out to create a specialized vehicle for tech-life sciences convergence, raising $350 million for their inaugural fund amid surging AI-biotech interest.[2][4] Early momentum came from deploying capital into 17 companies over two years, including buzzy AI plays, while evolving from a 2022 registration to a registered investment adviser (RIA) with $350 million AUM.[1][6] Pivotal moments include rapid deal flow—13 investments in the last 12 months—and announcing Dimension II in December 2024, cementing their track record.[1][2][3]
Dimension rides the explosive trend of AI infiltrating biotech, from generative biology to drug development tools, where compute meets biology's infinite potential amid persistent data gaps that shield innovators from scaling limits.[2][3][5] Timing is ideal: post-2023 AI boom, life sciences lags in data abundance, creating moats for platforms in discovery, manufacturing, and clinical stages—unlike commoditized AI elsewhere.[3] Market forces like pharma's need for efficiency and VC's shift to bio-AI (evident in Dimension's quick $500M raise) favor them, influencing the ecosystem by funding 22+ startups that digitize lab work and accelerate therapies, bridging tech VCs with bio specialists.[1][2][4] This positions Dimension as a catalyst in a $100B+ sector, amplifying founder impact where science and tech curves overlap.
Dimension's trajectory points to aggressive deployment of Dimension II into AI-biotech hybrids, potentially scaling to 20+ annual deals as data moats deepen and pharma partnerships grow.[3] Trends like multimodal AI for precision medicine (e.g., Odyssey Therapeutics) and high-performance infra (Modal Labs) will shape them, evolving their influence from niche investor to ecosystem shaper amid bio's AI gold rush.[2][5] Watch for larger growth bets and exits as portfolio matures—tying back to their mission, they're primed to redefine life's trajectory through compute-biology fusion.
